1. Scrip
  2. >>Business
  3. >>Deals

Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb

 
• By Alaric DeArment

The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.

Novartis sold Xiidra and ophthalmology pipeline assets to Bausch + Lomb • Source: Shutterstock

Novartis AG is continuing to streamline its portfolio in a deal with Bausch + Lomb, Corporation that involves offloading “front of eye” ophthalmology products, particularly a marketed treatment for dry eye disease (DED) and pipeline assets under development that include a drug-delivery device for dry eye indications and one for chronic ocular surface pain (COSP). For Bausch + Lomb, it allows the company to expand its already considerable presence in ophthalmology, including in DED.

The Swiss drug maker said 30 June that it had signed an agreement with Bausch + Lomb worth up to $2.5bn, including $1.75bn upfront and additional milestones

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.